Skip to main content
Erschienen in: Tumor Biology 7/2016

14.01.2016 | Original Article

ECRG4 as a novel tumor suppressor gene inhibits colorectal cancer cell growth in vitro and in vivo

verfasst von: Zhengxu Cai, Pin Liang, Jize Xuan, Jiajia Wan, Huishu Guo

Erschienen in: Tumor Biology | Ausgabe 7/2016

Einloggen, um Zugang zu erhalten

Abstract

Esophageal cancer related gene 4 (ECRG4) as a tumor suppressor gene inhibits the growth and development of various tumors. Colorectal cancer (CRC), a common malignant tumor in the digestive tract worldwide, is a leading cause of death. The aim of our study was to assess the tumor-suppressing effect of ECRG4 on CRC and explore its related mechanisms in vitro and in vivo. The expression levels of ECRG4 were measured in colorectal cancer tissues and para-carcinoma tissues. ECRG4 gene was transfected into CRC cells to investigate its effect on cell proliferation by MTT, colony formation assay, and cell cycle analysis. Cell apoptosis was assessed by annexin-V/PI, Hoechst 33342 staining, and analysis of apoptosis-related protein expressions in vitro. The in vivo tumorigenesis assays were performed in nude mice. According to the results, there was a lower expression of ECRG4 in CRC tissues compared with normal tissues, which was strongly associated with histology differentiation and lymph node metastasis. Additionally, overexpression of ECRG4 had a significant inhibitory effect on proliferation and promoted apoptosis in Caco-2 and SW480 cells. Moreover, we found that the overexpression of ECRG4 inhibited tumorigenesis in vivo by diminishing the volume and weight of the tumors and inducing apoptosis of tumor cells. Our study indicates that ECRG4 may be a new potential target and prognostic factor for patients with CRC.
Literatur
1.
2.
Zurück zum Zitat Laszlo L. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer. Magy Onkol. 2010;54:383–94.CrossRefPubMed Laszlo L. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer. Magy Onkol. 2010;54:383–94.CrossRefPubMed
3.
Zurück zum Zitat Vargas AJ, Thompson PA. Diet and nutrient factors in colorectal cancer risk. Nutr Clin Pract. 2012;27:613–23.CrossRefPubMed Vargas AJ, Thompson PA. Diet and nutrient factors in colorectal cancer risk. Nutr Clin Pract. 2012;27:613–23.CrossRefPubMed
4.
Zurück zum Zitat Bi MX, Han WD, Lu SX. Using lab on-line to clone and identify the esophageal cancer related gene 4. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai). 2001;33:257–61. Bi MX, Han WD, Lu SX. Using lab on-line to clone and identify the esophageal cancer related gene 4. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai). 2001;33:257–61.
5.
Zurück zum Zitat Su T, Liu H, Lu S. [Cloning and identification of cDNA fragments related to human esophageal cancer]. Zhonghua Zhong Liu Za Zhi. 1998;20:254–7.PubMed Su T, Liu H, Lu S. [Cloning and identification of cDNA fragments related to human esophageal cancer]. Zhonghua Zhong Liu Za Zhi. 1998;20:254–7.PubMed
6.
Zurück zum Zitat Li LW, Yu XY, Yang Y, Zhang CP, Guo LP, Lu SH. Expression of esophageal cancer related gene 4 (ECRG4), a novel tumor suppressor gene, in esophageal cancer and its inhibitory effect on the tumor growth in vitro and in vivo. Int J Cancer. 2009;125:1505–13.CrossRefPubMed Li LW, Yu XY, Yang Y, Zhang CP, Guo LP, Lu SH. Expression of esophageal cancer related gene 4 (ECRG4), a novel tumor suppressor gene, in esophageal cancer and its inhibitory effect on the tumor growth in vitro and in vivo. Int J Cancer. 2009;125:1505–13.CrossRefPubMed
7.
Zurück zum Zitat Li LW, Yang Y, Li XY, Guo LP, Zhou Y, Lu SX. [Tumor-suppressing function of human esophageal cancer related gene 4 in esophageal squamous cell carcinoma]. Zhonghua Yi Xue Za Zhi. 2010;90:2713–7.PubMed Li LW, Yang Y, Li XY, Guo LP, Zhou Y, Lu SX. [Tumor-suppressing function of human esophageal cancer related gene 4 in esophageal squamous cell carcinoma]. Zhonghua Yi Xue Za Zhi. 2010;90:2713–7.PubMed
8.
Zurück zum Zitat You Y, Yang W, Qin X, Wang F, Li H, Lin C, et al. ECRG4 acts as a tumor suppressor and as a determinant of chemotherapy resistance in human nasopharyngeal carcinoma. Cell Oncol (Dordr). 2015;38:205–14.CrossRef You Y, Yang W, Qin X, Wang F, Li H, Lin C, et al. ECRG4 acts as a tumor suppressor and as a determinant of chemotherapy resistance in human nasopharyngeal carcinoma. Cell Oncol (Dordr). 2015;38:205–14.CrossRef
9.
Zurück zum Zitat Xu T, Xiao D, Zhang X. ECRG4 inhibits growth and invasiveness of squamous cell carcinoma of the head and neck and in vivo. Oncol Lett. 2013;5:1921–6.PubMedPubMedCentral Xu T, Xiao D, Zhang X. ECRG4 inhibits growth and invasiveness of squamous cell carcinoma of the head and neck and in vivo. Oncol Lett. 2013;5:1921–6.PubMedPubMedCentral
10.
Zurück zum Zitat Li W, Liu X, Zhang B, Qi D, Zhang L, Jin Y, et al. Overexpression of candidate tumor suppressor ECRG4 inhibits glioma proliferation and invasion. J Exp Clin Cancer Res. 2010;29:89.CrossRefPubMedPubMedCentral Li W, Liu X, Zhang B, Qi D, Zhang L, Jin Y, et al. Overexpression of candidate tumor suppressor ECRG4 inhibits glioma proliferation and invasion. J Exp Clin Cancer Res. 2010;29:89.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Wang YB, Ba CF. Promoter methylation of esophageal cancer-related gene 4 in gastric cancer tissue and its clinical significance. Hepatogastroenterology. 2012;59:1696–8.CrossRefPubMed Wang YB, Ba CF. Promoter methylation of esophageal cancer-related gene 4 in gastric cancer tissue and its clinical significance. Hepatogastroenterology. 2012;59:1696–8.CrossRefPubMed
12.
Zurück zum Zitat Fang WJ, Zheng Y, Wu LM, Ke QH, Shen H, Yuan Y, et al. Genome-wide analysis of aberrant DNA methylation for identification of potential biomarkers in colorectal cancer patients. Asian Pac J Cancer Prev. 2012;13:1917–21.CrossRefPubMed Fang WJ, Zheng Y, Wu LM, Ke QH, Shen H, Yuan Y, et al. Genome-wide analysis of aberrant DNA methylation for identification of potential biomarkers in colorectal cancer patients. Asian Pac J Cancer Prev. 2012;13:1917–21.CrossRefPubMed
13.
Zurück zum Zitat Gotze S, Feldhaus V, Traska T, Wolter M, Reifenberger G, Tannapfel A, et al. ECRG4 is a candidate tumor suppressor gene frequently hypermethylated in colorectal carcinoma and glioma. BMC Cancer. 2009;9:447.CrossRefPubMedPubMedCentral Gotze S, Feldhaus V, Traska T, Wolter M, Reifenberger G, Tannapfel A, et al. ECRG4 is a candidate tumor suppressor gene frequently hypermethylated in colorectal carcinoma and glioma. BMC Cancer. 2009;9:447.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Vanaja DK, Ehrich M, Van den Boom D, Cheville JC, Karnes RJ, Tindall DJ, et al. Hypermethylation of genes for diagnosis and risk stratification of prostate cancer. Cancer Invest. 2009;27:549–60.CrossRefPubMedPubMedCentral Vanaja DK, Ehrich M, Van den Boom D, Cheville JC, Karnes RJ, Tindall DJ, et al. Hypermethylation of genes for diagnosis and risk stratification of prostate cancer. Cancer Invest. 2009;27:549–60.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Yue CM, Deng DJ, Bi MX, Guo LP, Lu SH. Expression of ECRG4, a novel esophageal cancer-related gene, downregulated by CpG island hypermethylation in human esophageal squamous cell carcinoma. World J Gastroenterol. 2003;9:1174–8.CrossRefPubMedPubMedCentral Yue CM, Deng DJ, Bi MX, Guo LP, Lu SH. Expression of ECRG4, a novel esophageal cancer-related gene, downregulated by CpG island hypermethylation in human esophageal squamous cell carcinoma. World J Gastroenterol. 2003;9:1174–8.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Kurabi A, Pak K, Dang X, Coimbra R, Eliceiri BP, Ryan AF, et al. Ecrg4 attenuates the inflammatory proliferative response of mucosal epithelial cells to infection. PLoS One. 2013;8:e61394.CrossRefPubMedPubMedCentral Kurabi A, Pak K, Dang X, Coimbra R, Eliceiri BP, Ryan AF, et al. Ecrg4 attenuates the inflammatory proliferative response of mucosal epithelial cells to infection. PLoS One. 2013;8:e61394.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Shaterian A, Kao S, Chen L, DiPietro LA, Coimbra R, Eliceiri BP, et al. The candidate tumor suppressor gene Ecrg4 as a wound terminating factor in cutaneous injury. Arch Dermatol Res. 2013;305:141–9.CrossRefPubMed Shaterian A, Kao S, Chen L, DiPietro LA, Coimbra R, Eliceiri BP, et al. The candidate tumor suppressor gene Ecrg4 as a wound terminating factor in cutaneous injury. Arch Dermatol Res. 2013;305:141–9.CrossRefPubMed
18.
Zurück zum Zitat Studzinski GP. Oncogenes, growth, and the cell cycle: an overview. Cell Tissue Kinet. 1989;22:405–24.PubMed Studzinski GP. Oncogenes, growth, and the cell cycle: an overview. Cell Tissue Kinet. 1989;22:405–24.PubMed
19.
Zurück zum Zitat Resnitzky D, Gossen M, Bujard H, Reed SI. Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system. Mol Cell Biol. 1994;14:1669–79.CrossRefPubMedPubMedCentral Resnitzky D, Gossen M, Bujard H, Reed SI. Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system. Mol Cell Biol. 1994;14:1669–79.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Musgrove EA. Cyclins: roles in mitogenic signaling and oncogenic transformation. Growth Factors. 2006;24:13–9.CrossRefPubMed Musgrove EA. Cyclins: roles in mitogenic signaling and oncogenic transformation. Growth Factors. 2006;24:13–9.CrossRefPubMed
21.
Zurück zum Zitat Botz J, Zerfass-Thome K, Spitkovsky D, Delius H, Vogt B, Eilers M, et al. Cell cycle regulation of the murine cyclin E gene depends on an E2F binding site in the promoter. Mol Cell Biol. 1996;16:3401–9.CrossRefPubMedPubMedCentral Botz J, Zerfass-Thome K, Spitkovsky D, Delius H, Vogt B, Eilers M, et al. Cell cycle regulation of the murine cyclin E gene depends on an E2F binding site in the promoter. Mol Cell Biol. 1996;16:3401–9.CrossRefPubMedPubMedCentral
22.
23.
Zurück zum Zitat Moirangthem DS, Laishram S, Borah JC, Kalita MC, Talukdar NC. Cephalotaxus griffithii Hook. f. needle extract induces cell cycle arrest, apoptosis and suppression of hTERT and hTR expression on human breast cancer cells. BMC Complement Altern Med. 2014;14:305.CrossRefPubMedPubMedCentral Moirangthem DS, Laishram S, Borah JC, Kalita MC, Talukdar NC. Cephalotaxus griffithii Hook. f. needle extract induces cell cycle arrest, apoptosis and suppression of hTERT and hTR expression on human breast cancer cells. BMC Complement Altern Med. 2014;14:305.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Porter AG, Janicke RU. Emerging roles of caspase-3 in apoptosis. Cell Death Differ. 1999;6:99–104.CrossRefPubMed Porter AG, Janicke RU. Emerging roles of caspase-3 in apoptosis. Cell Death Differ. 1999;6:99–104.CrossRefPubMed
26.
Zurück zum Zitat Lin C, Holland Jr RE, Donofrio JC, McCoy MH, Tudor LR, Chambers TM. Caspase activation in equine influenza virus induced apoptotic cell death. Vet Microbiol. 2002;84:357–65.CrossRefPubMed Lin C, Holland Jr RE, Donofrio JC, McCoy MH, Tudor LR, Chambers TM. Caspase activation in equine influenza virus induced apoptotic cell death. Vet Microbiol. 2002;84:357–65.CrossRefPubMed
27.
Zurück zum Zitat Min Z, Wang L, Jin J, Wang X, Zhu B, Chen H, et al. Pyrroloquinoline quinone induces cancer cell apoptosis via mitochondrial-dependent pathway and down-regulating cellular Bcl-2 protein expression. J Cancer. 2014;5:609–24.CrossRefPubMedPubMedCentral Min Z, Wang L, Jin J, Wang X, Zhu B, Chen H, et al. Pyrroloquinoline quinone induces cancer cell apoptosis via mitochondrial-dependent pathway and down-regulating cellular Bcl-2 protein expression. J Cancer. 2014;5:609–24.CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Ryu MJ, Chung HS. [10]-Gingerol induces mitochondrial apoptosis through activation of MAPK pathway in HCT116 human colon cancer cells. In Vitro Cell Dev Biol Anim. 2015;51:92–101.CrossRefPubMed Ryu MJ, Chung HS. [10]-Gingerol induces mitochondrial apoptosis through activation of MAPK pathway in HCT116 human colon cancer cells. In Vitro Cell Dev Biol Anim. 2015;51:92–101.CrossRefPubMed
29.
Zurück zum Zitat Rosse T, Olivier R, Monney L, Rager M, Conus S, Fellay I, et al. Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c. Nature. 1998;391:496–9.CrossRefPubMed Rosse T, Olivier R, Monney L, Rager M, Conus S, Fellay I, et al. Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c. Nature. 1998;391:496–9.CrossRefPubMed
30.
Zurück zum Zitat Borner C. The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. Mol Immunol. 2003;39:615–47.CrossRefPubMed Borner C. The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. Mol Immunol. 2003;39:615–47.CrossRefPubMed
Metadaten
Titel
ECRG4 as a novel tumor suppressor gene inhibits colorectal cancer cell growth in vitro and in vivo
verfasst von
Zhengxu Cai
Pin Liang
Jize Xuan
Jiajia Wan
Huishu Guo
Publikationsdatum
14.01.2016
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 7/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4775-2

Weitere Artikel der Ausgabe 7/2016

Tumor Biology 7/2016 Zur Ausgabe

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.